Skip to main content

Advertisement

SpringerLink
Log in

Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

We aimed to describe, in a daily clinical practice setting, the demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS), to compare the characteristics of patients receiving 5-alpha-reductase inhibitors (5-ARIs) with those not receiving them and to investigate predictors of 5-ARI prescription.

Methods

We performed a retrospective observational study using data retrieved from a general practitioners database. Male patients with diagnosis of BPH-LUTS were included. The following demographic and clinical data were available and extracted: age, comorbidities, BPH-LUTS medical therapy, drugs for comorbidities. A subgroup analysis was performed according to the use of 5-ARIs. Factors associated with 5-ARI prescription were assessed with uni- and multivariate analyses.

Results

A total of 7,103 patients were identified. Most patients (71.7 %) were aged ≥65 years. Hypertension was present in 64.9 % of patients; it was the most prevalent comorbidity followed by diabetes mellitus, hypercholesterolemia, coronary artery disease and other dyslipidemias. Overall, 38.22 % of patients were treated with 5-ARIs. Mean age of patients taking 5-ARIs was significantly higher. The prevalence of hypertension and the use of antihypertensive drugs were significantly higher among patients receiving 5-ARIs. Older age was an independent predictor of 5-ARI prescription.

Conclusions

In a daily clinical practice setting, patients with BPH-LUTS receiving 5-ARIs are significantly older and have significantly higher prevalence of hypertension if compared with patients with BPH-LUTS not receiving 5-ARIs. Older age is an independent predictor of 5-ARI prescription.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, Begaud B, Berges R, Borkowski A, Chappel CR, Costello A, Dobronski P, Farmer RD, Jiménez Cruz F, Jonas U, MacRae K, Pientka L, Rutten FF, van Schayck CP, Speakman MJ, Sturkenboom MC, Tiellac P, Tubaro A, Vallencien G, Vela Navarrete R (2002) Triumph Pan European Expert Panel. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care—the Triumph project. Eur Urol 42(4):323–328

    Article  CAS  PubMed  Google Scholar 

  2. AUA practice guidelines committee (2003) AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. J Urol 170:530–547

    Article  Google Scholar 

  3. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N’Dow J, Nordling J, de la Rosette JJ, European Association of Urology (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118–140

    Article  PubMed  Google Scholar 

  4. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F, CombAT Study Group (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57(1):123–131

    Article  PubMed  Google Scholar 

  5. Erdemir F, Harbin A, Hellstrom WJ (2008) 5-Alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med 5(12):2917–2924

    Article  PubMed  Google Scholar 

  6. Gur S, Kadowitz PJ, Hellstrom WJ (2013) Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf 12(1):81–90

    Article  CAS  PubMed  Google Scholar 

  7. Seftel A, Rosen R, Kuritzky L (2007) Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Int J Impot Res 19(4):386–392

    Article  CAS  PubMed  Google Scholar 

  8. Burnett AL (2006) The role of nitric oxide in erectile dysfunction: implications for medical therapy. J Clin Hypertens 8:53–62

    Article  CAS  Google Scholar 

  9. Napalkov P, Maisonneuve P, Boyle P (1995) Worldwide patterns of prevalence and mortality from benign prostatic hyperplasia. Urology 46:41–46

    Article  CAS  PubMed  Google Scholar 

  10. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387–2398

    Article  CAS  PubMed  Google Scholar 

  11. McVary KT (2006) BPH: epidemiology and comorbidities. Am J Manag Care 12(5 Suppl):S122–S128

    PubMed  Google Scholar 

  12. Sarma AV, Kellogg Parsons J (2009) Diabetes and benign prostatic hyperplasia: emerging clinical connections. Curr Urol Rep 10(4):267–275

    Article  PubMed  Google Scholar 

  13. Stamatiou K, Lardas M, Kostakos E, Koutsonasios V, Michail E (2009) The impact of diabetes type 2 in the pathogenesis of benign prostatic hyperplasia: a review. Adv Urol 1–3. doi:10.1155/2009/818965

  14. Lekili M, Müezzinoğlu T, Uyanik BS, Büyüksu C (2006) Serum lipid levels in benign prostatic hyperplasia. World J Urol 24(2):210–213

    Article  CAS  PubMed  Google Scholar 

  15. Andriole GL, Kirby R (2003) Safety and tolerability of the dual 5-alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 44:82–88

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

This study was approved by the ethics committee and was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

All participants gave their informed consent prior to their inclusion in the study.

Author information

Authors and Affiliations

  1. Urologic Clinic, University Federico II of Naples, Naples, Italy

    Ferdinando Fusco, Davide Arcaniolo, Nicola Longo, Paolo Verze, Francesco Mangiapia & Vincenzo Mirone

  2. Urologic Unit, Buon Consiglio Fatebenefratelli Hospital, Via Manzoni, 220, 80123, Naples, Italy

    Massimiliano Creta & Vittorio Imperatore

  3. SIMG, Italian Society of General Medicine, Florence, Italy

    Gaetano Piccinocchi, Giovanni Arpino & Matteo Laringe

  4. University “Campus Biomedico” of Rome, Rome, Italy

    Roberto Piccinocchi

Authors
  1. Ferdinando Fusco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Davide Arcaniolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Massimiliano Creta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gaetano Piccinocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giovanni Arpino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Matteo Laringe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Roberto Piccinocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nicola Longo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Paolo Verze
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Francesco Mangiapia
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Vittorio Imperatore
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Vincenzo Mirone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimiliano Creta.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fusco, F., Arcaniolo, D., Creta, M. et al. Demographic and comorbidity profile of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a real-life clinical setting: Are 5-alpha-reductase inhibitor consumers different?. World J Urol 33, 685–689 (2015). https://doi.org/10.1007/s00345-014-1460-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-014-1460-9

Keywords

Search

Navigation